Rapid Communication
Copyright ©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 21, 2007; 13(7): 1090-1097
Published online Feb 21, 2007. doi: 10.3748/wjg.v13.i7.1090
Table 1 Informative microsatellite markers were selected and used in this study
No.LocusMarkersGenetic map(cM)ForwardReversePCR productsize (bp)result1
18p23.3D8S7Not listedACCCTGACAGCAGAGGTTTCACCCTGACGTTCTCCCAGTA250-252ni
28p23.2D8S1164Not listedCACAAATCAGATTTTTGAAGTTGCGGGTTAGACGGACAACCTCA225ni
38p23.2D8S2640.7ACATCTGCGTCGTCTTCATACCAACACCTGAGTCAGCATA121-145in
48p23.2D8S2624.3AGCTCAAAAGCGAAGGTGATGGCAACAAAGTGAGATCCTG114-128in
58p23.1sts-X53793Not listedTCGACTACCCAGTGGTCTTGGTTCAAAATGCTTGCTCGC127ni
68p23.1D8S1742Not listedCCCCCACCAAGACACACTCAAGGGATATGAAGGGCA130in
78p23.1D8S2778.2GATTTGTCCTCATGCAGTGTACATGTTATGTTTGAGAGGTCTG121in
88p23.1D8S1918Not listedGAATGTCATGCTGGGAACGGTAGCTCTCAAAGCAAATTATGAGC108ni
98p23.1D8S181910TCACTGAGGGACTTGGCCGTGCTGAGAATGAGACC207in
108p23.1D8S1140Not listedGACAACATCCGATAATGCTGGAGGACATCTAGATAATTGGAAGA378ni
118p23.1D8S50316.2GGTTACGAGTTTTGTCCTTTGGAAACAAACCAATGTAGGAGTG136in
128p23.1D8S1672Not listedAACTGAGATCACGCCACTCCCCCATTGGTTTTAGAGTGGC149ni
138p23.1AFM234ve1Not listedTACCGCAAAACACACCAGCAGCCTTAGTTGACAACA245ni
148p23.1D8S2045Not listedCCGATTGCTTCATCGGGACCGCCTCCTCCTCTGAAATCCT120ni
158p23.1D8S113022.4GAAGATTTGGCTCTGTTGGATGTCTTACTGCTATAGCTTTCATAA145in
168p23.1D8S1946Not listedGCACAAGATCAGAGAGGTTGTGGAGGAGAGATGGTGTTGGGA102ni
178p23.1D8S1640Not listedTGCAGTCTGCGGGAGTTCAGCAGGGTGACTGTAAAGAAGG175ni
188p23.1D8S2060Not listedCTCTCCGGGAATGTAATACTGCGAGCTGGGAGTTACTGCCTG256ni
198p23.1D8S55226.4CCTGTACCATACCCCTGTATCAAGGTTTGAATCTCTCAGTGG132in
208p23.1D8S110926.4TTCTCAGAATTGCTCATAGTGCTCAGCTCCTCTTCTGCTGAT241in
218p23.1D8S2066Not listedTTTTCTCCATCCGGTGACTCCCAACTACGGCATGGTTTCT175ni
228p23.1-22D8S110626.5TTGTTTACCCCTGCATCACTTTCTCAGAATTGCTCATAGTGC149ni
238p22D8S1451Not listedAACCTAAGGTTCTGTGCTACATCAAACTTACCAAGGCCGTTTAGG149ni
248p22EST465487Not listedTTTGTTTGGGTGGAGGACTCTGGACATCTGCCTAGGTCCT250ni
258p22D8S1647Not listedCCAGAATTTTGAAATAGATTCATCCAAATTTTGTAAATATCAGTGTTCCG174ni
268p22stSG2938832GCAGTGAGATTTTGCTTCTGGATGAACATTCAATGAATCAGCA125ni
278p22D8S1713Not listedCAGGGGCTGATTGTCAGAACGTGGCTGTCACCAAGGTCTC113ni
288p22SGC33312Not listedAGGGCCTTGGGAACACTCTCAGTTTAAATGGATGGTTTTTACT137ni
298p22D8S2080Not listedGACTCAAAGAGAACCTGCCGTAGGTTGGTGAGCACACGTC132ni
308p22D8S2081Not listedACCCAGTTACAGCACTGTAATATCACTCTACCCCGAAATGATGGA147ni
318p22SHGC-24261Not listedAAGCAGAGATAAGCCCGACATTTCTTTAGATGGAGTCCATTGC123ni
328p22SHGC-52401Not listedACAGGATAGTGTTAGGCTCACATGCATTCTCTGTATCTTTTGGGGG120ni
338p22D8S254Not listedTGCCGGACATACATTAGTGATTGTAAACACCACAAGCAGG65-75in
348p22D8S2001Not listedGACATTGAATTCCAGTATTTGTGCGGACAAATGCCACTGCAAC138ni
358p22SHGC-5873Not listedGACACACACATACAGAAAACCACTTACCATGAATGGAGCTTG225ni
368p22D8S26135.8TGCCACTGTCTTGAAAATCCTATGGCCCAGCAATGTGTAT128in
378p22AFM234vf4Not listedGGGCACAGGCATGTGTGGCTGCATTCTGAAAGGTTA260-272ni
388p22D8S1948Not listedTTACAAAACATACCCAGTGTTTGGCTTTTTAGTGCTTGAGACTGTCTCC110ni
398p22D8S2028Not listedTCAAAAGTTTTGTTTCTATTCAGGGTTTTTTCTGTTCCCCTCCG178ni
408p22D8S25840.3CTGCCAGGAATCAACTGAGTTGACAGGGACCCACG144-154in
418p22D8S1949Not listedTGTCTTACAGCTCTCCCTCTCCCAGTAAGGATCACCAAGACAAGG106ni
428p22D8S1983Not listedATTGGAAGAGGCAAATGGTGTATGTACTGGATGAAGCAGGACA175ni
438p22D8S1786Not listedCGAAAGATTGAGACCCCATGTTTCCACACCGAAGCC209ni
448p22D8S29842.7AGGCTTACACCCATGGACCACGCAGCACACAACATCAT155-167in
458p21.3D8S2050Not listedTGCCAATATCAGTGGAAGAGGTCCTTTTTCCCTTGTTGCC162ni
468p21.3D8S1752Not listedTCCTGGATCAGGCAGAAATCAGAGTTGGGTGAGCGA140in
478p21.3D8S173444.9GCTATCCACTTGTCCCAGAAGCCCAGAAATAAACCCTC114in
488p21.2D8S2256Not listedGTGTCTTGAGATACTGGTGAGAGAAATGTCTTTGTTGAGG101ni
498p21.2D8S2259Not listedTGAAAGCCTGTTTAGAGAGACTATTGCCCTGTGTTTTGCC105ni
508p21.2D8S1220Not listedTTCCGTATACACATGCACCCTAGCAGCCAGACACAGGAGC90ni
518p21.1D8S1445Not listedGCAACAGAGCGAGACTCCGTCAAGCTTACATTCTGGGTGAC117-139in
528p21.1D8S2261Not listedGTATTTATTCCACAAGCATCTTACAACCCCATCAGTCTCTCTAAT204ni
538p21.1D8S1444Not listedTTCTTCTAGATTTCCTACTACATTTGTTAAAAGTACAACC91x
548p21D8S2249Not listedTCCACCCATTTCAGCCTTTCCTAAAACATTTAACTTTCATT101ni
558p21D8S2248Not listedATACAGGTAGGTGAGGGCAATTCTGATGCTCTTCTGGAGT136ni
568p21D8S2247Not listedCATTGTGGTGGAGGTCGGAGTTCCCCCATCCCATCTGAG122ni
578p21D8S2262Not listedATGTTTTGTTCATGGGTCTTTAAGAAAAAGGGAAGGGGCAGT98ni
588p21D8S339Not listedTAGATGTTACCATTTCACGATTAGATCTTGGATCAG162ni
598p21D8S2245Not listedCCTCTTTATCCCACTTTTCAGCATTTTACGAATATAAGCATCC138ni
608p21D8S2244Not listedACAACTAAAGGACTTAAAGGGACAAGAAAAGAACAAATGG145ni
618p21D8S2246Not listedTAACCTGTGAATGAGAATACTGACAGTTTTGAGAGAATCC169ni
Table 2 LOH status for the 8p23.2, 8p23.1, and 8p22 in hepatocellular carcinoma
CaseAgeSexSt/MtGradingEtiologyD8S264D8S2628p23.2D8S1742D8S277D8S1819D8S503D8S1130D8S552D8S11098p23.1D8S254D8S261D8S258D8S2988p22D8S1752D8S1734D8S14458p218p23.2-21
1260MMtMDAlcoholicninininininininini
1164MStMDCH(C)+, LCninininininini
142MStPDCH(B)+nininininininini
259MStMDCH(-)nininininini
2769MMtPDCH(C)+nininininininini
2658MStMDCH(C)+, LCnininini
1531FMtMDCH(C)+ninininininininininininini
2973MStWDCH(C)+ninininininininini
672MStMDCH(C)+ninininininininini
2065MStWDAlcoholic, LCnini
874MMtMDCH(-)nininininininini
759MMtWDCH(B)+, (C)+ninininini
1950MMtMDCH(B)+, LCninini
2858MMtMDCH(B)+ninininininini
551MMtMDCH(B)+nininininininininininini
1071FMtMDCH(C)+, LCninininininini
457MMtMDCH(C)+, LCnini
1374MMtMDCH(-)nininininininininininininini
1851MStWDCH(B)+, LCnininininininininini
1654MMtMDAlcoholic, LCnininininininininini
2571MStMDCH(B)+, (C)+nininininininininininini
3056MStMDCH(C)+ninininininininini
957MStWDCH(C)+nininininininininininini
351MStMDCH(B)+nininininininini
3254FStMDCH(B)+, LCninini
2167MStWDCH(C)+, LCninininininininininininini
3376FStWDCH(C)+, LCnininininini
2371MMtMDCH(-)ninininininininininininini
2265MMtMDCH(C)+ninininininininininini
3165FMtMDCH(C)+, LCninininininininininini
1737FMtMDCH(B)+, LCnininininininininininininininini
2460MMtMDCH(-), LCnininininininini
LOH ●0113425934161018215321420
Informative (32/33)8131617161212237173123101613322323313232
LOH/Informative (58/264 = 22%)0%8%6%a18%25%17%42%39%43%24%52%b43%10%50%15%47%c13%9%3%13%d63%e
Table 3 Distribution of LOH frequency at 8p in hepatocellular carcinoma cases by clinicopathological variables
ClinicopathologicalVariablesD8S264D8S2628p23.2D8S1742D8S277D8S1819D8S503D8S1130D8S552D8S11098p23.1D8S254D8S261D8S258D8S2988p22D8S1752D8S1734D8S14458p218p23.2-21
Tumor size (mm)
> 500/40/40/5 (0%)0/61/50/62/44/120/13/810/14 (71%)4/100/53/71/66/13 (46%)0/100/100/150/15 (0%)10/15 (67%)
< 500/31/71/8 (13%)3/113/112/63/75/113/61/96/17 (35%)6/131/75/91/79/16 (56%)3/112/141/154/15 (27%)10/17 (59%)
Tumor number
St0/20/30/5 (0%)1/91/81/52/63/121/33/106/15 (41%)9/181/64/71/74/13 (31%)3/202/181/244/24 (17%)17/24 (71%)
Mt0/51/101/10 (10%)2/73/81/63/66/112/41/710/16 (63%)1/40/44/91/65/13 (38%)0/20/50/70/7 (0%)2/7 (29%)
Growth Pattern
Eg0/81/131/15 (7%)3/164/132/114/119/223/73/1514/28 (50%)8/201/87/142/1313/26 (50%)3/202/211/294/29 (14%)18/29 (62%)
Ig0/10/10/1 (0%)0/10/30/21/10/10/01/22/5 (40%)2/20/21/20/02/2 (100%)0/20/20/20/2 (0%)2/2 (100%)
Formation of capsule
Fc-0/61/81/10 (10%)2/31/41/42/34/73/42/55/6 (83%)3/41/33/30/35/5 (100%)2/51/50/52/5 (40%)5/5 (100%)
Fc+0/20/60/6 (0%)1/143/121/83/95/170/32/1211/25 (44%)7/180/75/132/1010/23 (43%)1/181/181/262/26 (8%)15/26 (58%)
Infiltration to capsule
Fc-Inf-0/61/81/10 (10%)1/51/70/73/53/80/42/87/11 (64%)3/100/54/90/37/15 (47%)1/101/120/151/15 (7%)10/15 (67%)
Fc-Inf+0/10/30/3 (0%)1/81/30/21/43/100/01/55/13 (38%)5/90/33/52/76/11 (55%)1/100/80/131/13 (8%)7/13 (54%)
Septal formation
Sf-0/00/30/3 (0%)1/72/61/73/53/81/42/57/13 (54%)5/90/55/91/47/15 (47%)1/120/120/161/16 (6%)9/16 (56%)
Sf+0/61/91/10 (10%)2/81/50/31/43/101/12/75/12 (42%)4/100/33/61/67/11 (64%)2/91/90/122/12 (17%)8/12 (67%)
Grading
WD0/30/30/4 (0%)1/42/42/41/24/61/41/24/8 (50%)3/61/23/51/53/7 (43%)1/71/71/72/7 (29%)4/7 (57%)
MD1/70/91/13 (8%)2/132/121/94/125/171/123/611/21 (52%)6/131/85/111/1310/18 (56%)2/121/130/212/21 (10%)13/21 (62%)
PD0/00/10/1 (0%)0/10/30/10/11/32/30/12/3 (67%)1/21/30/10/01/2 (50%)0/20/20/20/2 (0%)2/2 (100%)
pT
pT10/10/20/2 (0%)0/20/10/10/11/20/30/20/5 (0%)2/60/12/31/23/6 (50%)0/60/60/60/6 (0%)3/6 (50%)
pT21/70/71/10 (10%)2/61/71/34/64/52/53/37/11 (64%)5/81/45/70/47/11 (64%)2/81/90/112/11 (18%)8/11 (73%)
pT30/20/20/3 (0%)1/42/21/30/23/81/50/15/8 (63%)2/40/10/21/42/5 (40%)1/51/51/82/8 (25%)5/8 (63%)
pT40/00/00/0 (0%)0/00/10/10/00/11/10/01/1 (100%)1/10/20/00/01/2 (50%)0/10/10/20/2 (0%)1/2 (50%)
pN
pN-1/80/101/12 (8%)3/73/72/43/56/91/80/15/12 (42%)4/90/06/72/78/13 (62%)3/112/101/134/13 (31%)9/13 (69%)
pNx0/00/30/3 (0%)0/61/50/41/42/92/61/56/12 (50%)2/40/61/50/12/4 (50%)0/50/50/70/7 (0%)4/7 (57%)
pM
pM-1/60/111/13 (8%)2/71/51/23/53/103/82/46/14 (43%)3/71/55/91/66/11 (55%)2/101/110/132/13 (15%)7/13 (54%)
pMx0/00/00/0 (0%)0/02/30/20/12/20/21/13/4 (75%)5/60/10/10/05/7 (71%)1/50/50/81/8 (13%)7/8 (88%)
Vascular infiltration
V-0/71/101/13 (8%)2/103/101/84/96/132/62/99/20 (45%)6/150/57/130/711/20 (55%)2/162/181/213/21 (14%)14/21 (67%)
V+1/70/21/9 (11%)1/71/61/41/33/101/12/87/11 (64%)4/61/51/32/64/7 (57%)1/60/50/91/9 (11%)5/9 (56%)
Bile duct infiltration
B-0/101/131/17 (6%)3/184/152/114/1310/243/93/1715/28 (54%)7/182/98/152/1211/24 (46%)2/192/201/273/27 (11%)16/27 (59%)
B+0/10/10/2 (0%)0/30/31/41/30/41/31/43/4 (75%)3/51/50/10/44/5 (80%)1/40/40/51/5 (20%)4/5 (80%)
Liver cirrhosis
LC-0/20/60/6 (0%)1/82/71/61/47/141/13/811/18 (61%)6/110/44/72/89/16 (56%)1/101/131/182/18 (11%)12/18 (67%)
LC+0/51/51/7 (14%)2/92/91/64/82/92/61/95/13 (38%)4/101/64/90/56/13 (46%)2/111/110/142/14 (14%)8/14 (57%)
Chronic hepatitis
CH-0/10/30/4 (0%)2/32/31/11/23/71/12/44/8 (50%)4/61/32/51/35/7 (71%)2/60/50/82/8 (25%)6/8 (75%)
CH+0/61/71/9 (11%)1/132/131/114/96/162/62/1312/23 (52%)6/170/76/111/1010/22 (45%)1/172/191/242/24 (8%)14/24 (58%)